Functional Comparison of Interferon‐α Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon‐α and Interferon‐γ Signaling

Jieliang Chen,Yaming Li,Fritz Lai,Yang Wang,Kathrin Sutter,Ulf Dittmer,Jianyu Ye,Wenjing Zai,Min Liu,Fang Shen,Min Wu,Kongying Hu,Baocun Li,Mengji Lu,Xiaonan Zhang,Jiming Zhang,Jianhua Li,Qingfeng Chen,Zhenghong Yuan
DOI: https://doi.org/10.1002/hep.31282
IF: 17.298
2021-02-01
Hepatology
Abstract:<section class="article-section__content"><p>Interferon‐α (IFN‐α), composed of numerous subtypes, plays a crucial role in immune defense. As the most‐studied subtype, IFN‐α2 has been used for treating chronic hepatitis B virus (HBV) infection with advantages of finite treatment duration and sustained virological response, but its efficacy remains relatively low. Here, we aimed to screen for IFN‐α subtype with the highest anti‐HBV potency and to characterize new mechanism of IFN‐α‐mediated HBV restriction. Using cell culture‐based HBV infection systems and a human liver chimeric mouse model, IFN‐α subtypes‐mediated antiviral response and signaling activation were comprehensively analyzed. IFN‐α14 was identified as the most effective subtype in suppression of HBV cccDNA transcription and HBeAg/HBsAg production, with IC<sub>50</sub> values approximately 100‐fold lower than the conventional IFN‐α2. IFN‐α14 alone elicited IFN‐α and ‐γ signaling crosstalk similarly to the combined use of IFN‐α2 and IFN‐γ, inducing multiple potent antiviral effectors, which synergistically restricted HBV replication. GBP5, one of the most differentially‐expressed genes between IFN‐α14‐ and ‐α2‐treated liver cells, was identified as a new HBV restriction factor. A strong IFN‐α‐IFNAR1 receptor subunit interaction determines the anti‐HBV activity of IFN‐α. The <i>in vivo</i> anti‐HBV activity of IFN‐α14 and treatment‐related transcriptional patterns were further confirmed, and little adverse effect was observed. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>A concerted IFN‐α and ‐γ response in liver, which could be efficiently elicited by IFN‐α subtype 14, is associated with potent HBV suppression. These data deepen our understanding of the divergent activities of IFN‐α subtypes and the mechanism underlying the synergism between IFN‐α and ‐γ signaling, with implications for improved IFN therapy and HBV cure strategies.</p></section>
gastroenterology & hepatology
What problem does this paper attempt to address?